Enterprise Value

-93.34M

Cash

180.9M

Avg Qtr Burn

-12.77M

Short % of Float

2.91%

Insider Ownership

0.88%

Institutional Own.

54.47%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Phase 1/2

Update

CX-904 (EGFRxCD3) Details
Cancer, Solid tumor/s

Phase 1

Data readout

CX-2029 (PDC directed against CD71) Details
Non-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s

Failed

Discontinued

Praluzatamab ravtansine (CX-2009) (anti-CD166) Details
Cancer, HER2-expressing cancers, Breast cancer

Failed

Discontinued

Failed

Discontinued